Respiratory Syncytial Virus Infection Clinical Trial
Official title:
Innate Immunity and RSV Infection in Children
In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.
Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the first 3 years of life. There are significant social and health care costs associated with RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die annually. Several longitudinal studies have also suggested that children who have RSV-LRIs are at substantially increased risk of developing asthma in the first 3 years after infection and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate the innate immune response through the pattern recognition receptor, Toll like receptor-4 (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It has been suggested that such a mechanism may result in altered immune responses to RSV infection and different clinical outcomes. This research has direct application to improving our understanding of bronchiolitis in early childhood, particularly those factors that influence severity of the disease, and may have implications for possible therapy of patients with bronchiolitis in the future. ;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02016690 -
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis
|
N/A | |
| Completed |
NCT01107535 -
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
|
N/A | |
| Completed |
NCT04491877 -
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
|
Phase 2 | |
| Completed |
NCT05987072 -
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
|
Phase 1 | |
| Completed |
NCT01006629 -
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06134648 -
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
|
Phase 1/Phase 2 | |
| Completed |
NCT03473002 -
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02135614 -
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
| Completed |
NCT01909843 -
ALX-0171 Safety Study in Adults With Hyperresponsive Airways
|
Phase 1 | |
| Recruiting |
NCT06206720 -
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
|
Phase 2 | |
| Completed |
NCT02254421 -
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
|
Phase 2 | |
| Recruiting |
NCT06237296 -
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
|
Phase 1 | |
| Completed |
NCT01537198 -
Surveillance of Synagis in Korean Pediatric Patients
|
N/A | |
| Recruiting |
NCT05687279 -
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
|
Phase 1/Phase 2 | |
| Completed |
NCT01297504 -
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
|
N/A | |
| Recruiting |
NCT06079320 -
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2/Phase 3 | |
| Completed |
NCT02309320 -
A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06194318 -
First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01466062 -
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
|
Phase 3 | |
| Active, not recruiting |
NCT04767373 -
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
|
Phase 2/Phase 3 |